<DOC>
	<DOCNO>NCT00578682</DOCNO>
	<brief_summary>To evaluate safety tolerability single IV dose MEDI-557 .</brief_summary>
	<brief_title>A Phase I , Randomized , Double-Blind , Single-Dose , Dose Escalation Study Evaluate Safety , Tolerability , Pharmacokinetics MEDI-557</brief_title>
	<detailed_description>The primary objective study evaluate safety tolerability single IV dose MEDI-557 administer healthy adult subject 4 dose cohort .</detailed_description>
	<criteria>Age 18 45 year time study entry ; Weight ≤ 90 kg ; Healthy medical history physical examination ; Normotensive ( systolic blood pressure [ BP ] &lt; 150 mmHg diastolic BP &lt; 90 mmHg ) ; Normal electrocardiogram ( ECG ) screening ( must occur within 21 day entry study ) ; Normal spirometry screening ( must occur within 21 day entry study ) . Normal spirometry define FEV1 ( forced expiratory volume 1 second ) FVC ( force vital capacity ) ≥ 80 % predict FEV1/FVC &gt; 70 % . Written inform consent obtain subject ; Sexually active female , unless surgically sterile , must use effective method avoid pregnancy ( include oral implanted contraceptive , intrauterine device , female condom spermicide , diaphragm spermicide , cervical cap , abstinence , use condom spermicide sexual partner sterile sexual partner ) 14 day prior study drug dosing , must agree continue use precaution 1 year administration study drug , must negative serum pregnancy test within 3 day prior study drug dose negative urine pregnancy test day study drug administration ; Ability complete followup period 240 day require protocol . Acute illness study entry ; Fever ≥ 99.5°F study entry ; Any drug therapy within 7 day prior Study Day 0 ( except contraceptive ) ; Blood donation excess 400 mL within 6 month prior study entry ; Receipt immunoglobulin blood product within 60 day prior study entry ; Receipt investigational drug therapy standard vaccine within 120 day prior study drug dose 240 day study drug dosing ; Previous receipt palivizumab motavizumab ; History immunodeficiency ; History allergic disease reaction likely exacerbate component either study drug ; Previous medical history evidence intercurrent illness may compromise safety subject study ; Evidence systemic disease physical examination ; Evidence infection ( ie , positive laboratory test result ) hepatitis A , B , C virus human immunodeficiency virus1 ( HIV1 ) ; At screening ( must within 21 day entry study ) following : hemoglobin &lt; 12.0 gm/dL , white blood cell count ( WBC ) &lt; 4,000/mm3 , platelet count &lt; 120,000/mm3 ( laboratory normal value ) ; aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) , blood urea nitrogen ( BUN ) , serum creatinine &gt; upper limit normal ( ULN ) ; abnormal laboratory value screen panel , opinion principal investigator , judge clinically significant ; abnormal laboratory value screen panel , opinion principal investigator , judge potentially confound analysis study result ; Pregnancy , nurse mother ; History alcohol drug abuse within past 2 year ; History asthma , seasonal allergy , exerciseinduced wheezing .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2011</verification_date>
</DOC>